Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30255427 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTTHRBPOLB | |
| SCHEMBL29554722 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTTHRBPOLB | |
| SCHEMBL30255294 | 1.00 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTTHRBPOLB | |
| SCHEMBL31161852 | 0.87 | MAPT (0.65) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL31161542 | 0.87 | MAPT (0.65) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL31161461 | 0.87 | MAPT (0.65) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL23783127 | 0.86 | GPR119 (0.41) | LMNAMAPTTHRB | |
| SCHEMBL30031402 | 0.86 | GPR119 (0.41) | LMNAMAPTTHRB | |
| SCHEMBL29554597 | 0.85 | GPR119 (0.42) | ALDH1A1LMNAMAPTTHRBSLC6A9 | |
| SCHEMBL23783227 | 0.85 | GPR119 (0.42) | ALDH1A1LMNAMAPTTHRBSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720516-A | Advantageous crystalline forms of selective BRD9 degrading agents | C4医药公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-115279370-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2022-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | ALDH1A1 4230/4885LMNA 2718/4885MAPT 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.